KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Ratio (2016 - 2025)

TherapeuticsMD's Equity Ratio history spans 16 years, with the latest figure at 0.71 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 1.24% year-over-year to 0.71; the TTM value through Dec 2025 reached 0.71, up 1.24%, while the annual FY2025 figure was 0.71, 1.24% up from the prior year.
  • Equity Ratio reached 0.71 in Q4 2025 per TXMD's latest filing, up from 0.71 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.71 in Q4 2025 to a low of 1.05 in Q1 2022.
  • Average Equity Ratio over 5 years is 0.28, with a median of 0.57 recorded in 2023.
  • Peak YoY movement for Equity Ratio: plummeted 2561.13% in 2022, then surged 425.92% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.55 in 2021, then soared by 170.33% to 0.39 in 2022, then soared by 74.06% to 0.68 in 2023, then rose by 4.26% to 0.71 in 2024, then grew by 1.24% to 0.71 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Equity Ratio are 0.71 (Q4 2025), 0.71 (Q3 2025), and 0.71 (Q2 2025).